Wound contraction is attenuated by fasudil inhibition of Rho-associated kinase

Plastic and Reconstructive Surgery

Volumn 128, Issue 5, 2011, Pages

  Bond, Jennifer E ^a,b   Kokosis, George ^a,b   Ren, Licheng ^a,b   Selim, M Angelica ^a,b   Bergeron, Andrew ^a,b   Levinson, Howard ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; DRUG DERIVATIVE; FASUDIL; PROTEIN KINASE INHIBITOR; RHO KINASE;

ADULT; ANIMAL; ARTICLE; COMPARATIVE STUDY; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FIBROBLAST; HUMAN; IMMUNOHISTOCHEMISTRY; INJURY; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; RAT; SCAR; SKIN; SUBCUTANEOUS DRUG ADMINISTRATION; WESTERN BLOTTING; WISTAR RAT; WOUND HEALING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADULT; ANIMALS; BIOPSY, NEEDLE; BLOTTING, WESTERN; CICATRIX; DISEASE MODELS, ANIMAL; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RANDOM ALLOCATION; RATS; RATS, WISTAR; RHO-ASSOCIATED KINASES; SKIN; WOUND HEALING; WOUNDS AND INJURIES;

EID: 80155183208     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e31822b7352     Document Type: Article

References (51)

1. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3:349-363.
2. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200:500-503.
3. Ridley AJ. The GTP-binding protein Rho. Int J Biochem Cell Biol. 1997;29:1225-1229.
4. Riento K, Ridley AJ. ROCKs: Multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4:446-456.
5. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med (Berl.) 2002;80:629-638.
6. Small EM, Thatcher JE, Sutherland LB, et al. Myocardinrelated transcription factor-A controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res. 2010;107:294-304.
7. Shi J, Wei L. Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp (Warsz.) 2007;55:61-75.
8. Asano T, Ikegaki I, Satoh S, et al. Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther. 1987;241:1033-1040.
9. Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: Results of a prospective placebo-controlled doubleblind trial. J Neurosurg. 1992;76:571-577.
10. Satoh S, Yamaguchi T, Hitomi A, et al. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol. 2002;455:169-174.
11. Tada S, Iwamoto H, Nakamuta M, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol. 2001;34:529-536.
12. Ikeda H, Kume Y, Tejima K, et al. Rho-kinase inhibitor prevents hepatocyte damage in acute liver injury induced by carbon tetrachloride in rats. Am J Physiol Gastrointest Liver Physiol. 2007;293:G911-G917.
13. Nagatoya K, Moriyama T, Kawada N, et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int. 2002;61:1684-1695.
14. Takeda Y, Nishikimi T, Akimoto K, Matsuoka H, Ishimitsu T. Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction. Hypertens Res. 2010;33:965-973.
15. Wang YX, da Cunha V, Martin-McNulty B, et al. Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Eur J Pharmacol. 2005;512:215-222.
16. Huntley BK, Ameenuddin S, Chen HH. Differential antifibrotic effects of vardenafil and fasudil in the heart and kidney of diabetic rats. J Card Fail. 2010;16:S31-S31.
17. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int. 2003;64:2009-2019.
18. Nishikimi T, Akimoto K, Wang X, et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens. 2004;22:1787-1796.
19. Arita R, Hata Y, Nakao S, et al. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 2009;58:215-226.
20. Bond JE,HoTQ, Selim MA, Hunter CL, Bowers EV, Levinson H. Temporal spatial expression and function of non-muscle myosin II isoforms IIA and IIB in scar remodeling. Lab Invest. 2011;91:499-508.
21. Grinnell F. Fibroblast collagen-matrix contraction: Growthfactor signalling and mechanical loading. Trends Cell Biol. 2000;10:362-365.
22. Grinnell F, Petroll WM. Cell motility and mechanics in threedimensional collagen matrices. Ann Rev Cell Dev Biol. 2010; 26:335-361.
23. Friel AM, Hynes PG, Sexton DJ, Smith TJ, Morrison JJ. Expression levels of mRNA for Rho A/Rho kinase and its role in isoprostane-induced vasoconstriction of human placental and maternal vessels. Reprod Sci. 2008;15:179-188.
24. da Silva-Santos JE, Chiao CW, Leite R, Webb RC. The Rho- A/Rho-kinase pathway is up-regulated but remains inhibited by cyclic guanosine monophosphate-dependent mechanisms during endotoxemia in small mesenteric arteries. Crit Care Med. 2009;37:1716-1723.
25. Arturson G. Prostaglandins in human burn-wound secretion. Burns 1977;3:112-118.
26. Wang J, Hori K, Ding J, et al. Toll-like receptors expressed by dermal fibroblasts contribute to hypertrophic scarring. J Cell Physiol. 2011;226:1265-1273.
27. Levinson H, Moyer KE, Saggers GC, Erlich HP. Calmodulinmyosin light chain kinase inhibition changes fibroblast-populated collagen lattice contraction, cell migration, focal adhesion formation, and wound contraction. Wound Repair Regen. 2004;12:505-511.
28. Rudolph R, Hurn I, Woodward M. Use of colchicine to inhibit wound contraction. Am J Surg. 1981;141:712-717.
29. Teo TC, Naylor IL. Modifications to the rate of wound contraction by allopurinol. Br J Plast Surg. 1995;48:198-202.
30. Tolazzi AR, Tolazzi KD, Garcia M, et al. Influence of leukotriene inhibitor montelukast on wound contraction and cutaneous healing process in rats. Aesthetic Plast Surg. 2009;33:84-89.
31. Fukushima M, Nakamuta M, Kohjima M, et al. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int. 2005;25:829-838.
32. Ying Z, Yue P, Xu X, et al. Air pollution and cardiac remodeling: A role for RhoA/Rho-kinase. Am J Physiol Heart Circ Physiol. 2009;296:H1540-H1550.
33. Desmouliére A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122:103-111.
34. Abe M, Ho CH, Kamm KE, Grinnell F. Different molecular motors mediate platelet-derived growth factor and lysophosphatidic acid-stimulated floating collagen matrix contraction. J Biol Chem. 2003;278:47707-47712.
35. Hirayama K, Hata Y, Noda Y, et al. The involvement of the rho-kinase pathway and its regulation in cytokine-induced collagen gel contraction by hyalocytes. Invest Ophthalmol Vis Sci. 2004;45:3896-3903.
36. Jiang H, Rhee S, Ho CH, Grinnell F. Distinguishing fibroblast promigratory and procontractile growth factor environments in 3-D collagen matrices. FASEB J. 2008;22:2151-2160.
37. Parizi M, Howard EW, Tomasek JJ. Regulation of LPA-promoted myofibroblast contraction: Role of Rho, myosin light chain kinase, and myosin light chain phosphatase. Exp Cell Res. 2000;254:210-220.
38. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996;15:2208-2216.
39. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem. 1995; 270:29051-29054.
40. Ishizaki T, Maekawa M, Fujisawa K, et al. The small GTPbinding protein Rho binds to and activates a 160 kDa Ser/ Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996;15:1885-1893.
41. Tomasek JJ, Vaughan MB, Kropp BP, et al. Contraction of myofibroblasts in granulation tissue is dependent on Rho/ Rho kinase/myosin light chain phosphatase activity. Wound Repair Regen. 2006;14:313-320.
42. Totsukawa G, Yamakita Y, Yamashiro S, Hartshorne DJ, Sasaki Y, Matsumura F. Distinct roles of ROCK (Rho-kinase) and MLXK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J Cell Biol. 2000;150:797-806.
43. Castella LF, Buscemi L, Godbout C, Meister JJ, Hinz B. A new lock-step mechanism of matrix remodelling based on subcellular contractile events. J Cell Sci. 2010;123:1751-1760.
44. Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005;91:391-392.
45. Fukui S, Fukumoto Y, Suzuki J, et al. Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol. 2008;51:317-326.
46. Ishimaru K, Ueno H, Kagitani S, Takabayashi D, Takata M, Inoue H. Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. J Cardiovasc Pharmacol. 2007;50:187-194.
47. Kanda T, Wakino S, Homma K, et al. Rho-kinase as a molecular target for insulin resistance and hypertension. FASEB J. 2006;20:169-171.
48. Bokoch GM. Regulation of innate immunity by Rho GTPases. Trends Cell Biol. 2005;15:163-171.
49. Aznar S, Lacal JC. Rho signals to cell growth and apoptosis. Cancer Lett. 2001;165:1-10.
50. Rupérez M, Sánchez-López E, Blanco-Colio LM, et al. The Rho-kinase pathway regulates angiotensin II-induced renal damage. Kidney Int Suppl. 2005;99:S39-S45.
51. Heusinger-Ribeiro J, Eberlein M, Wahab NA, Goppelt- Struebe M. Expression of connective tissue growth factor in human renal fibroblasts: Regulatory roles of RhoA and cAMP. J Am Soc Nephrol. 2001;12:1853-1861.